Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited has announced a strategic partnership with Medicxi for developing a novel cancer therapy, marking progress with their proprietary DEP® dendrimer technology. They’re gearing up for significant exposure at the ASCO Annual Meeting with two oral presentations on their clinical programs. The company maintains a strong financial position, ending the quarter with a cash balance of $26.6 million, and anticipates reduced cash outflows as clinical trials conclude.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
